HIGH SCHOOL EDITION
Journal of Student Research
Volume 13 Issue 1 (2024)

Understanding Alzheimer's Disease: Exploring Neuropsychiatric Symptoms and Treatment Options

Alexander Strofs

Stevenson School, USA

ABSTRACT

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects millions worldwide, leading to cognitive decline and neuropsychiatric symptoms. This paper provides a comprehensive review of AD, its pathogenesis, and the impact of neuropsychiatric symptoms. It explores AD's historical context and the pivotal role of brain regions in its pathogenesis. AD presents a significant public health challenge, with nearly 50 million individuals affected globally and a growing prevalence. The pathogenesis of AD involves the accumulation of amyloid-β plaques, tau tangles, vascular abnormalities, mitochondrial dysfunction, oxidative stress, and neuroinflammation. These factors contribute to progressive neurodegeneration and cognitive decline. Genetic factors, neuroimaging, and neuropathological studies shed light on the mechanisms underlying these symptoms. Past medications, such as cholinesterase inhibitors, antipsychotics, and serotonergic agents, have been used to manage neuropsychiatric symptoms in AD. However, their efficacy varies, and some carry risks. Recent clinical trials have explored potential anti-amyloid agents and non-pharmacological therapies. These studies highlight the need for innovative treatments. Non-pharmacological therapies, including physical activity, cognitive stimulation, social engagement, environmental modifications, caregiver education, and sensory-based interventions, aim to improve the quality of life for individuals with AD and their caregivers. Clinical trials suggest that physical fitness interventions and cognitive stimulation, particularly virtual reality, hold promise. Aromatherapy has shown the potential to enhance cognitive function in AD. Understanding the complexity of AD and its neuropsychiatric symptoms is essential for developing effective treatment strategies. While progress has been made, further research is needed to improve the lives of those affected by this devastating neurodegenerative disorder.

Introduction

Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder that profoundly impacts the lives of millions worldwide. As the leading cause of dementia, AD affects cognitive function and daily living activities, making it a significant public health concern[1]. This introduction aims to provide an overview of AD, delving into the brain regions implicated in the disease, its historical context, and its substantial prevalence, emphasizing the importance of understanding and addressing this devastating condition.

AD is characterized by the intricate interplay of various brain regions, with the medial temporal lobe and neocortical structures playing pivotal roles in the pathogenesis[2]. These areas are profoundly impacted, leading to cognitive decline and memory impairment, characteristic features of AD[3]. The presence of extracellular amyloid plaques and intracellular neurofibrillary tangles further contributes to neuropathology, disrupting synaptic and neuronal function and ultimately leading to neuronal loss[2].

The historical roots of AD can be traced back to the early 20th century when Alois Alzheimer, a German psychiatrist, made groundbreaking discoveries that shaped our understanding of this debilitating disorder[4].

Alois Alzheimer observed amyloid plaques and significant neuronal loss in the brain of his first patient, who exhibited memory loss and personality changes, providing the basis for the disease's name and identification[5].

The prevalence of AD is staggering, affecting nearly 50 million people globally, and is projected to increase significantly by 2050[6]. This substantial burden on individuals, families, and healthcare systems underscores the urgency of further research and investment in AD. As the world's population grows, AD poses a critical public health challenge, demanding comprehensive early detection, management, and care strategies.

This paper aims to provide a comprehensive literature review on AD, focusing on the brain regions implicated in the disease, its pathophysiological features, and the most common neuropsychiatric symptoms associated with AD. Additionally, we will explore past medications and therapies used for AD treatment and investigate potential treatments currently in clinical trials. Understanding the mechanisms behind neuropsychiatric symptoms and exploring innovative therapeutic approaches is essential for enhancing the quality of life for individuals affected by AD and addressing the growing global impact of this devastating neurodegenerative disorder.

What is the Pathogenesis of Alzheimer's Disease?

The pathogenesis of Alzheimer's disease (AD) is characterized by a complex interplay of multiple factors that lead to the progressive neurodegeneration observed in affected individuals. Despite extensive research, the exact mechanisms triggering and driving AD remain not fully elucidated. One of the central neuropathological hallmarks of AD is the accumulation of amyloid-β (Aβ) plaques in the brain parenchyma and cerebral vasculature[7]. Aβ peptides, derived from the amyloid precursor protein (APP) through enzymatic cleavage, aggregate to form plaques that initiate an inflammatory and immune response, leading to cellular damage and neurodegeneration[8]. This inflammatory response involves microglia activation and cytokine release, ultimately resulting in neuronal cell death and cognitive decline. Another hallmark is the presence of intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau protein. Tau proteins, normally involved in stabilizing microtubules, become hyperphosphorylated and misfolded, leading to their aggregation into tangles that disrupt cellular function. These tangles contribute to the loss of synaptic connections between neurons and further exacerbate cognitive decline. The interplay between Aβ plaques and tau tangles is believed to create a vicious cycle of neurotoxicity, with each component influencing the accumulation and aggregation of the other. Vascular abnormalities, mitochondrial dysfunction, oxidative stress, reduced brain glucose utilization, and neuroinflammation are also implicated as key contributors to AD pathogenesis[9]. Vascular changes, including impaired blood flow and the breakdown of the blood-brain barrier, may exacerbate Aβ accumulation and neuroinflammation[10]. Mitochondrial dysfunction leads to energy deficits and increased oxidative stress, contributing to neuronal damage.

Additionally, oxidative stress and inflammation further propagate neurodegeneration by damaging cellular components and promoting the accumulation of misfolded proteins, creating a vicious cycle[11]. While these mechanisms provide a framework for understanding AD's progression, the disease's complexity suggests that multiple factors interact to initiate and drive the pathogenic process.

In conclusion, the pathogenesis of Alzheimer's disease is a multifaceted process involving the accumulation of Aβ plaques, the formation of tau tangles, vascular abnormalities, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The intricate interplay between these factors results in the progressive neurodegeneration and cognitive decline characteristic of the disease. Despite significant advancements in our understanding of AD's mechanisms, further research is needed to uncover the precise triggers and drivers of the disease, allowing for the development of more targeted and effective therapeutic interventions[12].

How Does Alzheimer's Disease Cause Neuropsychiatric Symptoms?

Alzheimer's disease is primarily characterized by cognitive decline, memory impairment, and functional deterioration. However, a substantial subset of individuals with AD experiences a diverse range of neuropsychiatric symptoms, including psychosis, apathy, and various behavioral and psychological symptoms of dementia (BPSD). AD leads to the emergence of these neuropsychiatric symptoms, where neuroimaging and neuropathological factors contribute to the discovery of this phenomenon.

Apathy is a common neuropsychiatric symptom frequently accompanying AD. Apathy is characterized by reduced motivation, initiative, and activity engagement. It often manifests as a lack of interest in previously enjoyed activities and a decline in social interaction, leading to further impairment in the quality of life for patients and caregivers[13]. The broader category of BPSD encompasses various behavioral and psychological symptoms that frequently co-occur in individuals with AD. These symptoms include agitation, aggression, depression, anxiety, irritability, sleep disturbances, and social withdrawal, among others. One of the significant implications of BPSD is the burden it places on caregivers and healthcare systems. As individuals with AD experience these symptoms, caregivers often grapple with increased emotional, physical, and psychological demands. Caring for a loved one with AD who displays BPSD can be emotionally draining and require substantial time and resources. Moreover, the presence of BPSD can contribute to greater utilization of healthcare services. Managing the challenging behaviors and psychological symptoms associated with AD may necessitate frequent medical consultations, adjustments in treatment plans, and specialized care, all of which can strain healthcare resources. Furthermore, BPSD is intricately linked to the overall trajectory of AD. Its presence can accelerate the cognitive and functional decline of individuals. The interaction between cognitive impairment and behavioral disturbances can create a vicious cycle where worsening cognitive abilities contribute to the manifestation of BPSD, which may lead to further deterioration in cognitive function[14] .

Genetic factors play a significant role in developing neuropsychiatric symptoms in AD. The heritability of psychosis in AD is estimated at 61%, indicating a strong genetic influence (30-32). Although specific genes associated with AD-related psychosis are yet to be identified, ongoing genome-wide association studies provide promising avenues for further exploration (37, 38). Similarly, genetic predisposition may contribute to apathy and other BPSD, although specific genes remain elucidated[15].

Neuroimaging studies offer valuable insights into the neural correlates of these neuropsychiatric symptoms. Individuals with AD and neuropsychiatric symptoms, such as apathy and BPSD, exhibit distinct patterns of neurodegeneration and synaptic impairment. Neuroimaging findings indicate reduced gray matter volume, regional blood flow, and regional glucose metabolism, particularly in neocortical regions[15]. These alterations underscore the profound impact of neuropsychiatric symptoms on neural circuitry.

Neuropathological studies further prove the complex interplay between AD pathology and neuropsychiatric symptoms. The accelerated accumulation of hyperphosphorylated tau protein, particularly in neocortical regions, contributes to more severe cognitive impairment and behavioral disturbances, including psychosis, apathy, and BPSD (58-61). Tau pathology appears to be a critical link between AD-related neurodegeneration and the emergence of these symptoms.

Neuropsychiatric symptoms, including psychosis, in AD, are believed to be associated with underlying pathological changes, such as the accumulation of amyloid-β and tau proteins. Studies have demonstrated a correlation between tau aggregation in the transentorhinal region, an area affected by early-stage tau pathology, and the severity of NPS, particularly affective symptoms. These findings suggest a potential link between tau pathology and affective symptoms in the early stages of AD[16].

Risk Factors of Alzheimer's Disease

The etiology of Alzheimer's disease (AD) involves various risk factors. Aging, a prominent factor, is closely associated with AD, with several characteristics of AD pathology observed in the aging brain. Genetic influences play a crucial role. Specific genes, such as those associated with early-onset familial AD (EO-FAD) and the APOE gene, are risk factors that have been identified. Traumatic brain injury and vascular factors lead to AD risk, supported by pathological investigations. Metabolic factors, including obesity and diabetes, immune system dysfunction, and metal exposure, have also emerged as potential contributors.

Furthermore, the intriguing possibility of infectious agents as risk factors has garnered attention. The intricacies of these risk factors are hypothesized through various models, including oxidative stress-induced free radical accumulation, the "dual hit" hypothesis involving gene-environment interactions, and the concept of allostatic load, where cumulative stress over an individual's lifespan contributes to AD pathology. This intricate web of risk factors underscores the intricate nature of AD development, warranting continued research efforts to decipher the underlying mechanisms and interactions that culminate in this debilitating neurological disorder[17].

Medications Used in The Past to Treat Neuropsychiatric Symptoms of Alzheimer's Disease

Medication classes have been utilized to manage NPS, including antipsychotics, cholinesterase inhibitors, and serotonergic agents. These medications have shown effectiveness in ameliorating psychosis and behavioral symptoms in AD patients, although the evidence is inconclusive for all medicines. It is worth noting that side effects can vary across medication classes and among individual patients[18]. Cholinesterase inhibitors, including drugs such as Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne), have been instrumental in the therapeutic landscape by inhibiting the breakdown of acetylcholine, a neurotransmitter central to cognitive function[19]. Another significant medication, Memantine (Namenda), operates as an NMDA receptor antagonist, modulating glutamate activity to mitigate cognitive decline[20]. Although these medications offer symptomatic relief and a degree of cognitive preservation, it is essential to underscore that they do not provide a cure for AD. The efficacy of these treatments varies among individuals, and while they may slow cognitive decline, a comprehensive solution for the disease remains elusive.

Antipsychotic medications are often prescribed to manage severe neuropsychiatric symptoms in Alzheimer's disease (AD) patients, particularly symptoms such as agitation, aggression, and psychosis. These medications work by modulating dopamine and other neurotransmitter systems in the brain. It's important to note that the use of antipsychotics in AD is associated with significant concerns and potential risks, including an increased risk of stroke, cardiovascular events, and mortality, particularly in elderly patients[21].

Risperidone is an atypical antipsychotic often used to manage agitation and aggression in AD patients. Despite its effectiveness in alleviating these symptoms, its use is associated with a higher risk of adverse events, particularly stroke and cardiovascular issues. Quetiapine is another atypical antipsychotic sometimes prescribed to address agitation and psychosis in AD patients. Its soothing properties may help manage sleep disturbances and anxiety, but caution is required due to potential side effects[22].

Serotonergic agents, particularly selective serotonin reuptake inhibitors (SSRIs), have been explored for their potential to manage various neuropsychiatric symptoms in AD, such as depression, anxiety, and irritability. These agents primarily modulate the serotonin neurotransmitter system, which is involved in mood regulation and emotional well-being[23] Sertraline is an SSRI that has shown promise in treating depression and anxiety in AD patients. It is generally well-tolerated and has a more favorable side-effect profile than other antidepressants. Citalopram is another SSRI that may be used to manage mood disturbances in AD patients. It's

important to note that dosing should be carefully monitored to avoid potential adverse effects, particularly in the elderly population.

What Are the Most Promising Potential Medications That Can Be Used to Treat the Neuropsychiatric Symptoms of Alzheimer's Disease?

Medications in conventional neuroleptics, atypical antipsychotics, cholinesterase inhibitors, and serotonergic classes have been utilized to treat NPS, including psychosis, in AD patients. Each type of medication may have distinct effects and side effect profiles, and the choice of drugs for an individual patient can be challenging. A clinical trial introduces the role of beta-amyloid (Aβ) in Alzheimer's disease (AD) and examines the efficacy of various anti-amyloid agents in clinical trials. Despite limited success in clinical trials, the article evaluates four potential agents: aducanumab, gantenerumab, BAN2401 (injectable antibodies), and ALZ-801 (small molecule oral agent). It discusses their pharmacological characteristics, such as selectivity for Aβ oligomers, brain penetration, and time to peak brain exposure, and how these factors influence their clinical profiles. ALZ-801 is highlighted as a promising selective anti-oligomer agent, and its upcoming phase 3 trial in APOE4/4 patients with early AD is mentioned. The article's keywords encompass AD, beta-amyloid oligomers, anti-oligomer agents, anti-amyloid antibodies, APOE4 genotype, and specific agents (aducanumab, gantenerumab, BAN2401, ALZ-801). Overall, this article provides valuable insights into the complex relationship between Aβ and AD and the potential of anti-amyloid agents in treating the disease[24].

Ashwagandha (Withania somnifera) is a promising potential medication for addressing the neuropsychiatric symptoms associated with Alzheimer's (AD). Traditional uses of Ashwagandha in Ayurvedic medicine have indicated its ability to improve memory, alleviate nervous exhaustion, and enhance cognitive function. Recent studies have delved into the pharmacological effects of Ashwagandha extracts and their constituents, particularly withanolides, in the context of neurodegenerative diseases. Notably, research has demonstrated that Ashwagandha extracts can induce neurite outgrowth and synaptic reconstruction, critical in countering the loss of neuronal networks observed in AD. Withanone, a compound found in Ashwagandha, has shown possible neuroprotective effects by preventing cell damage induced by neurotoxic agents. Furthermore, studies have explored Ashwagandha's role in facilitating axonal growth and recovery in spinal cord injury, further highlighting its neurodegenerative potential. While these findings suggest that Ashwagandha may hold promise in mitigating neuropsychiatric symptoms in AD, more clinical trials are needed to ascertain its safety in addressing Alzheimer's disease[25,26].

What Are the Current Nonpharmacological Therapies Used to Treat Alzheimer’s Disease?

The current non-pharmacological therapies used to treat neuropsychiatric symptoms of Alzheimer's disease (AD) aim to alleviate behavioral and psychological symptoms of dementia (BPSD) and improve the overall quality of life for individuals with AD and their caregivers. These therapies complement drug-based approaches and address the diverse neuropsychiatric symptoms commonly associated with AD. Multidomain interventions involve a combination of non-pharmacological activities, such as physical activity, cognitive training, and improved nutrition, to manage neuropsychiatric symptoms. These activities can help improve mood, reduce agitation and aggression, and enhance overall well-being. Non-pharmacological strategies manage specific BPSD, such as agitation, aggression, anxiety, depression, and sleep disturbances. These strategies may include behavioral interventions, sensory stimulation, music therapy, pet therapy, and validation therapy. Each approach is tailored to the individual's needs and preferences[27].

Engaging individuals with AD in regular physical activity can help reduce restlessness, aggression, and anxiety while promoting a sense of accomplishment and social engagement. Exercise programs may include walking, stretching, and other activities that suit the individual's physical abilities. Cognitive stimulation activities like puzzles, games, and reminiscence therapy aim to engage and stimulate cognitive function. These activities can reduce symptoms of depression, anxiety, and social withdrawal. Encouraging social interactions and participation in group activities can help alleviate feelings of loneliness, isolation, and depression. Social engagement programs, such as group discussions, art classes, and support groups, provide opportunities for individuals with AD to connect with others and enhance their emotional well-being.

Creating a supportive and soothing environment can positively impact neuropsychiatric symptoms. Environmental modifications may include optimizing lighting, reducing noise levels, and using calming colors and decor to promote relaxation and reduce agitation. Educating caregivers about AD and providing coping strategies and support is essential for managing neuropsychiatric symptoms. Caregiver education programs can help caregivers better understand and respond to the behaviors and needs of individuals with AD. Validation therapy involves empathetic communication and validating the individual's feelings and emotions. This approach can help reduce distress, anxiety, and frustration by acknowledging the individual's experiences and emotions. Music and art therapies offer creative outlets that evoke positive emotions and enhance cognitive stimulation. Listening to music or engaging in art can help manage agitation, anxiety, and mood disturbances. Sensory-based interventions, such as aromatherapy, massage, and multisensory environments, provide sensory input that can promote relaxation and reduce agitation and anxiety[28].These non-pharmacological therapies offer a comprehensive and holistic approach to addressing the neuropsychiatric symptoms of AD. While their effectiveness may vary for each individual, these therapies enhance the overall well-being and quality of life of individuals with AD and their caregivers.

What Are the Most Promising Nonpharmacological Therapies Used to Treat Alzheimer's Disease Based On Trials?

In a randomized controlled trial to present compelling evidence of noteworthy enhancement in VO2peak (a fundamental measure of cardiorespiratory fitness) through a structured exercise intervention in individuals afflicted with mild Alzheimer's disease (AD). Intriguing correlation surfaces between enhancements in VO2peak and concurrent improvements in cognitive performance, as measured by the Symbol Digit Modalities Test, and neuropsychiatric symptomatology, gauged through the Neuropsychiatric Inventory. These results propose a potential interplay between improved fitness and cognitive and neuropsychiatric well-being in mild AD patients[29]. Another study found that older adults with mild-to-moderate Alzheimer's disease can participate in aerobic exercise interventions and potentially improve their cardiorespiratory fitness, despite their cognitive symptoms. This suggests that structured, individualized exercise programs could positively affect physical fitness in this population[26]. These studies show it is evident that Physical fitness will help with the treatment of Alzheimer's disease.

Based on evidence from a clinical trial, cognitive simulation, particularly virtual reality-based mental stimulation, holds promise as a nonpharmacological therapy for treating Alzheimer's disease. The positive impact on global cognitive functioning, high retention rates, and alignment with previous research suggests that cognitive simulation has the potential to contribute to the management of AD. However, further research is needed to explore specific cognitive domains, consider the role of cognitive reserve, investigate different levels of VR immersion, and address limitations related to study design and control groups[30].

A clinical trial study found significant improvements in cognitive function among dementia patients, particularly in the ability to form abstract ideas. The study identified enhanced abstract function scores in patients with mild to moderate AD after aromatherapy. This improvement suggests that aromatherapy positively

influences cognitive abilities, which is a central symptom of AD. The Touch Panel-type Dementia Assessment Scale (TDAS) results showed improvements in concept understanding after aromatherapy. The TDAS scores demonstrated an overall enhancement in cognitive function for all patient groups, including those with AD. Patients exhibited significant improvements in their TDAS scores, indicating a positive effect of aromatherapy on cognitive abilities. Lastly, Routine laboratory tests, including blood analysis and biochemical examination, showed no significant changes before and after aromatherapy, suggesting that the treatment is safe and devoid of deleterious side-effects. Based on the results of the study, aromatherapy appears to be a promising nonpharmacological therapy that can be used to treat Alzheimer's disease. The improvements in cognitive function, particularly abstract thinking and concept understanding, observed in AD patients after aromatherapy provide evidence of its potential efficacy in enhancing cognitive abilities[31].

Discussion

In conclusion, Alzheimer's disease poses a substantial health challenge due to its profound impact. Neuropsychiatric symptoms further contribute to the burden of the disease. This research paper has explored the various aspects of Alzheimer's disease, including the involvement of specific brain regions, historical background, prevalence, and the significance of understanding the disease. Additionally, the paper has provided insights into common neuropsychiatric symptoms, past and potential medication treatments, and potential therapies in clinical trials. However, it is essential to acknowledge the limitations of existing research and continue investigating novel approaches to enhance the quality of life for individuals living with Alzheimer's disease.

Acknowledgments

I would like to thank my advisor for the valuable insight provided to me on this topic.

References

1. De-Paula, V. J., Radanovic, M., Diniz, B. S. & Forlenza, O. V. Alzheimer’s disease. *Subcell. Biochem.* 65, 329–352 (2012).

2. Breijyeh, Z. & Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. *Molecules* 25, (2020).
3. Blackman, J. *et al.* Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer’s disease: A systematic review. *J. Sleep Res.* 30, e13229 (2021).

4. Serý, O., Povová, J., Míšek, I., Pešák, L. & Janout, V. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. *Folia Neuropathol.* 51, 1–9 (2013).

5. Ferrari, C. & Sorbi, S. The complexity of Alzheimer’s disease: an evolving puzzle. *Physiol. Rev.* 101, 1047–1081 (2021).

6. Kumar, A., Sidhu, J., Goyal, A. & Tsao, J. W. *Alzheimer Disease*. (StatPearls Publishing, 2022).

7. Rostagno, A. A. Pathogenesis of Alzheimer’s Disease. *Int. J. Mol. Sci.* 24, (2022).

8. Chow, V. W., Mattson, M. P., Wong, P. C. & Gleichmann, M. An overview of APP processing enzymes and products. *Neuromolecular Med.* 12, 1–12 (2010).

9. Zhang, H. *et al.* Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease. *Int. J. Biol. Sci.* 17, 2181–2192 (2021).

10. Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat. Rev. Neurol.* 14, 133–150 (2018).

11. Fischer, R. & Maier, O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. *Oxid. Med. Cell. Longev.* 2015, 610813 (2015).

12. Khan, S., Barve, K. H. & Kumar, M. S. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. *Curr. Neuropharmacol.* 18, 1106–1125 (2020).

13. Teixeira, A. L., Gonzales, M. M., de Souza, L. C. & Weisenbach, S. L. Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches. *Behav. Neurol.* 2021, 6319826 (2021).

14. Malara, A. *et al.* Pain Assessment in Elderly with Behavioral and Psychological Symptoms of Dementia. *J. Alzheimers. Dis.* 50, 1217–1225 (2016).

15. Murray, P. S., Kumar, S., Demichele-Sweet, M. A. A. & Sweet, R. A. Psychosis in Alzheimer's disease. *Biol. Psychiatry* 75, 542–552 (2014).

16. Gumus, M., Multani, N., Mack, M. L., Tartaglia, M. C. & Alzheimer's Disease Neuroimaging Initiative. Progression of neuropsychiatric symptoms in young-onset versus late-onset Alzheimer's disease. *Geroscience* 43, 213–223 (2021).

17. A Armstrong, R. Risk factors for Alzheimer's disease. *Folia Neuropathol.* 57, 87–105 (2019).

18. Yasuno, F., Minami, H., Hattori, H. & Alzheimer's Disease Neuroimaging Initiative. Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study. *Int. J. Geriatr. Psychiatry* 36, 598–605 (2021).

19. Birks, J. S. [No title]. *Cochrane Database Syst. Rev.* (2006) doi:10.1002/14651858.CD005593.

20. Tariot, P. N. *et al.* Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 291, 317–324 (2004).

21. Ballard, C. & Howard, R. Neuroleptic drugs in dementia: benefits and harm. *Nat. Rev. Neurosci.* 7, 492–500 (2006).

22. Ballard, C. & Waite, J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst. Rev.* CD003476 (2006)

23. Seitz, D. P. *et al.* Antidepressants for agitation and psychosis in dementia. *Cochrane Database Syst. Rev.* CD008191 (2011).

24. Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A. & Sabbagh, M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. *Alzheimers. Res. Ther.* 12, 95 (2020).

25. Kuboyama, T., Tohda, C. & Komatsu, K. Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. *Biol. Pharm. Bull.* 37, 892–897 (2014)

26. Sarris, J. *et al.* Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J. Biol. Psychiatry* 23, 424–455 (2022)

27. Passeri, E. *et al.* Alzheimer's Disease: Treatment Strategies and Their Limitations. *Int. J. Mol. Sci.* 23, (2022).

28. Sobol, N. A. *et al.* Change in Fitness and the Relation to Change in Cognition and Neuropsychiatric Symptoms After Aerobic Exercise in Patients with Mild Alzheimer's Disease. *J. Alzheimers. Dis.* 65, 137–145 (2018).

29. Yu, F., Savik, K., Wyman, J. F. & Bronas, U. G. Maintaining physical fitness and function in Alzheimer's disease: a pilot study. *Am. J. Alzheimers. Dis. Other Demen.* 26, 406–412 (2011).

30. Oliveira, J. *et al.* Virtual Reality-Based Cognitive Stimulation on People with Mild to Moderate Dementia due to Alzheimer's Disease: A Pilot Randomized Controlled Trial. *Int. J. Environ. Res. Public Health* 18, (2021).

31. Jimbo, D., Kimura, Y., Taniguchi, M., Inoue, M. & Urakami, K. Effect of aromatherapy on patients with Alzheimer's disease. *Psychogeriatrics* 9, 173–179 (2009).